Mesenchymal stem cells (MSCs) and the FDA

mscs-and-fda-post

Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be found in many tissues throughout the body, including the bone marrow, adipose tissue, and umbilical cord. MSCs have the ability to differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. Additionally, MSCs can be used for a variety of regenerative medicine applications, such as tissue engineering and cell-based therapies. The U.S. Food and Drug Administration (FDA) is responsible for regulating the use of MSCs in the United States. Currently, the FDA has not approved any MSC-based products for use in humans. However, the FDA has issued guidance documents that provide recommendations for the development and manufacturing of MSC-based products. These guidance documents are not binding, but companies that develop MSC-based products are encouraged to follow them. The FDA has also established a regulatory pathway for the Investigational New Drug (IND) application process for MSC-based products. This pathway provides a framework for companies to submit IND applications to the FDA for review and approval. The FDA has also created a working group, called the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC), which provides scientific and clinical advice on the development and regulation of MSC-based products. The FDA’s regulation of MSC-based products is ongoing, and the agency continues to evaluate new data as it becomes available. The FDA will continue to work with companies to ensure that MSC-based products are safe and effective for their intended use.